Byetta Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Litigation for Byetta Lawsuits, Other Incretin Mimetic Claims

The Firm is evaluating potential Byetta lawsuits alleging an association between the use of Byetta and pancreatic cancer.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
Our Firm has received numerous Byetta lawsuit inquiries from individuals concerned about the alleged association between Byetta and pancreatic cancer. We are pleased to see this litigation moving forward.

New York, New York (PRWEB) November 08, 2013

Byetta lawsuits (http://www.byettalawsuit2013.com/) and other product liability claims involving the use of diabetes drugs known as incretin mimetics continue to move forward in a multidistrict litigation underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to court documents, the Court has scheduled the proceeding’s next Status Conference for November 21st. Court records further indicate that at least 150 claims alleging an association between diabetes drugs like Byetta and pancreatic cancer have been filed in the proceeding. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“Our Firm has received numerous Byetta lawsuit inquiries from individuals concerned about the alleged association between Byetta and pancreatic cancer. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free case evaluations to patients who took Byetta and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.

Byetta and Pancreatic Cancer
According to court documents, at least 150 lawsuits have been filed in the Southern District of California alleging an association between the use of incretin mimetic drugs, including Byetta, and pancreatic cancer. All of the claims accuse the manufacturers of these medications of failing to provide doctors and patients with adequate warnings regarding this potential risk.

Court documents indicate that the litigation involving Byetta and similar drugs began to grow substantially after the U.S. Food & Drug Administration (FDA) announced this past March that it was investigating findings from an unpublished study that indicated drugs like Byetta could cause precancerous changes in the cells of the pancreas. The FDA has since noted that it was unable to reach any conclusion regarding this possible risk, but its review is ongoing.

Byetta was brought to market in 2005, and was the first of the incretin mimetics class of Type 2 diabetes drugs. In 2008, the FDA issued a public warning about Byetta after receiving a high number of reports involving pancreatitis in patients who took the drug.* In February 2011,a study published in the medical journal, Gastroenterology, suggested that patients taking Byetta faced a 3-fold increased risk of developing pancreatic cancer, as well as a 6-fold increased risk of pancreatitis. The same study also reported 30 cases of thyroid cancer among Byetta patients.**

In April, the Institute for Safe Medicine Practices revealed that the FDA’s Adverse Event Reporting Database had received 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta in a single 12-month period.*** In June, the British Medical Journal reported that an analysis of clinical trial data indicated that the manufacturers of Byetta and other incretin mimetics may have downplayed their potential to harm the pancreas.****

Byetta users who have been diagnosed with pancreatic cancer, pancreatitis, or thyroid cancer may be entitled to file a Byetta lawsuit. Click Here to learn more about the alleged association between Byetta and pancreatic cancer at Bernstein Liebhard LLP’s website. To schedule a free case review, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm, FDA, August 18, 2008
**gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
****http://www.bmj.com/content/346/bmj.f3680, British Medical Journal, June 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.byettalawsuit2013.com/